Sonrotoclax

索托克拉

Report date: 2026/05/20 17:55:29
NME

Base Information

Drug NameSonrotoclax
Drug Alias Name百悦达BEQALZIBGB-11417
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative Diseases +[17] 
Global Approved IndicationsLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryMainland China
Original Approved Date2025/12/30
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeOne Medicines USA IncShanghai Jiao Tong University School of MedicineNational Cancer Institute +[6] 
Inactive CompaniesN/A
Active IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative Diseases +[16] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A